

Pralatrexate

Printed from <https://www.cancerquest.org/node/6420> on 02/08/2025

Pralatrexate 2D

Brand name: Folutyn®

IUPAC: (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl]amino]pentanedioic acid

FDA approval: Yes

[Enlace del fabricante](#)

Usage:

Folutyn is given through a vein by intravenous (IV) injection. Folic acid and vitamin B12 supplements are also prescribed during treatment with Folutyn® to reduce the risk of possible side effects. Take as prescribed. The amount of Folutyn® that you will receive depends on many factors, your general health or other health problems, and the type of cancer or condition being treated.

Mechanism:

Folutyn belongs to the class of chemotherapy drugs called antimetabolites. Antimetabolites are very similar to normal substances within the cell. When the cells incorporate these substances into the cellular metabolism, they are unable to divide. Antimetabolites are cell-cycle specific. They attack cells at very specific phases in the cycle. Folutyn is classified as a folic acid antagonist.

Side effects:

Side effects include: mouth sores, low platelet count, nausea, fatigue, anemia, constipation, fever, swelling.